Brokerages Anticipate Aimmune Therapeutics Inc (NASDAQ:AIMT) Will Announce Earnings of -$1.01 Per Share

Wall Street analysts forecast that Aimmune Therapeutics Inc (NASDAQ:AIMT) will post earnings per share (EPS) of ($1.01) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Aimmune Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($1.10). Aimmune Therapeutics posted earnings of ($0.89) per share during the same quarter last year, which would indicate a negative year over year growth rate of 13.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Aimmune Therapeutics will report full-year earnings of ($4.00) per share for the current fiscal year, with EPS estimates ranging from ($4.26) to ($3.68). For the next year, analysts expect that the business will post earnings of ($3.31) per share, with EPS estimates ranging from ($4.06) to ($2.48). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Aimmune Therapeutics.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.08). During the same period last year, the business earned ($0.91) earnings per share.



Several research analysts have recently commented on AIMT shares. ValuEngine raised Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reissued a “buy” rating and issued a $45.00 target price on shares of Aimmune Therapeutics in a report on Thursday, May 9th. Roth Capital began coverage on shares of Aimmune Therapeutics in a research report on Friday, July 12th. They issued a “buy” rating and a $45.00 price objective for the company. Finally, BidaskClub upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $42.50.

A number of hedge funds have recently bought and sold shares of the stock. Voloridge Investment Management LLC acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth about $682,000. Pictet Asset Management Ltd. acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth about $1,374,000. Nuveen Asset Management LLC acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth about $3,969,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Aimmune Therapeutics by 11.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock worth $109,234,000 after buying an additional 535,072 shares during the last quarter. Finally, OneAscent Financial Services LLC acquired a new position in shares of Aimmune Therapeutics during the 2nd quarter worth about $273,000. Hedge funds and other institutional investors own 75.85% of the company’s stock.

Shares of AIMT opened at $21.79 on Tuesday. The company has a market capitalization of $1.35 billion, a P/E ratio of -5.94 and a beta of -0.07. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 7.65. Aimmune Therapeutics has a one year low of $16.95 and a one year high of $36.12. The business’s 50 day simple moving average is $19.58 and its 200-day simple moving average is $21.22.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Article: Total Return

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.